Metabolic risks remain largely unmonitored in Medicaid patients taking antipsychotics
Despite government warnings and professional recommendations about diabetes risks associated with second-generation antipsychotic drugs, fewer than one-third of Medicaid patients who are treated with these medications undergo tests of blood glucose or lipid levels, according to a report in the January issue of Archives of General Psychiatry , one ...
Join the discussion below, or Read more at EurekAlert!.
#1 Jan 4, 2010
At the same time regulatory agencies were warning of Zyprexa’s possible linkage to diabetes, Lilly’s second most lucrative product line was its diabetes treatment drugs (including Actos, Humulin, and Humalog), which collectively grossed $2.51 billion in 2003. Lilly’s profits on diabetes drugs and the possible linkage between diabetes and Zyprexa is not, however, the most recent Lillygate that Gardiner Harris broke about Zyprexa in the New York Times on December 18, 2003.
Eli Lilly, Zyprexa, & the Bush family
Add your comments below
|Sarah Baker, M.D., Joins CHI Memorial Medical G...||Sep '17||doper||1|
|Betsy Long: Alleged wrong-way drunk driver is... (Jul '10)||Dec '16||Professional Drun...||41|
|Fake drugs bought on the web pose big health risks (Jan '10)||Jan '16||Casey||24|
|barring codes in water fear (Dec '15)||Dec '15||flopzzzz||2|
|Court record showing Colo. massacre 'shooter' w... (Aug '12)||Aug '15||pathetic||2|
|Hundreds rally, seek end to strikes on Gaza (Jul '14)||Jul '14||Garry Ackerman||2|
|Rheumatologist chat: Get answers to your health... (Mar '14)||Mar '14||Jenn||1|
Find what you want!
Search University of Colorado Denver Forum Now
Copyright © 2017 Topix LLC